stockrow
Friday 6 November 2026
Export ALUR’s income statement to Excel — free account
Allurion Technologies, Inc.
ALUR Healthcare Medical Devices
Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024.
- Revenue
- −47.2%
- EPS
- −46.5%
- Free cash flow
- +66.0%
Quarter to March 2026, against a year earlier
0.00
0.00
NaN
Follow ALUR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 64 | 53 | 32 | 15 | 13 | (38.1%) | 14 | 24 | — | +25.3% | |
| Gross margin, % | — | — | — | — | — | — | 79.00 | 77.61 | 66.97 | 62.84 | 52.70 | (16.2) pt | ||||||
| EBT | — | — | — | — | 0 | 6 | (38) | (83) | (6) | (29) | (33) | +460.2% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | (58.56) | (154.40) | (20.18) | (188.32) | (264.73) | (188.3) pt | ||||||
| Net income | — | 0 | — | — | 0 | 6 | (38) | (83) | (7) | (29) | (33) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 894.30 | 563.40 | 214.21 | 30.26 | 14.15 | n/m | |||||
| Earnings | — | — | — | — | (0.10) | 101.59 | (525.56) | (865.82) | (48.03) | (57.15) | (57.79) | +253.7% | ||||||
| Cash flow | — | — | — | — | 0.00 | (36.62) | (654.33) | (674.20) | (282.19) | (57.51) | (25.49) | n/m | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (21.59) | (16.92) | (4.08) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | 0.00 | (36.62) | (675.92) | (691.13) | (286.26) | (57.51) | (25.49) | n/m | ||||||
| Book value | — | — | — | — | 0.40 | (1,084.94) | (450.06) | (751.29) | (520.20) | (153.37) | (87.49) | n/m | ||||||
| Shares, m | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 1 | +58.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 2.35 | 0.75 | 0.61 | 0.00 | 0.9 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 2.73 | 2.60 | 4.93 | 5.25 | 2.6 | ||||||
| EV/FCF | — | — | — | — | — | — | (6.62) | (2.23) | (1.94) | (2.54) | (2.84) | (3.3) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (2) | (47) | (64) | (42) | (29) | (23) | n/m | |||||
| Capex | — | — | — | — | — | — | (2) | (2) | (1) | — | (1) | (37.2%) | ||||||
| Free cash flow | — | — | — | — | 0 | (2) | (49) | (66) | (43) | (29) | (23) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 1 | (32) | (1) | 8 | (26) | (26) | +149.9% | |||||
| Net debt | — | — | — | — | 0 | 1 | 49 | 1 | 20 | (5) | (5) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | 0 | (62) | (32) | (71) | (78) | (77) | (78) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (3.15) | 1.33 | (8.88) | (137.33) | (13.77) | (118.37) | (127.26) | (115.2) pt | |||||
| ROIC | — | — | — | — | (2.28) | 0.00 | (121.52) | 0.00 | 0.00 | 0.00 | 0.00 | +2.3 pt | ||||||
| ROE | — | — | — | — | 0.00 | (18.74) | 86.65 | 163.14 | 9.64 | 37.06 | 45.16 | +37.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 252 | 137 | 41 | — | (59.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.21 | 0.23 | 0.37 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Allurion Technologies, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NNOX Nano-X Imaging Ltd. | $19.6M | — (loss-making) | — (loss-making) | +36.71% (above 0%: growing) | n/m | −21.37% (below 0%: shrinking) | (1,050.87%) | (1,334.91%) | Compare |
| SNWV Sanuwave Health Inc. | $19.4M | 1.2× | — (loss-making) | −3.13% (below 0%: shrinking) | n/m | +86.75% (above 0%: growing) | 76.23% | (2.88%) | Compare |
| PMI Flag Ship Acquisition Corp | $19.3M | — (loss-making) | — (loss-making) | +38.62% (above 0%: growing) | n/m | +46.79% (above 0%: growing) | 20.85% | (156.70%) | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | — (loss-making) | — (loss-making) | −47.19% (below 0%: shrinking) | n/m | +65.98% (above 0%: growing) | 41.70% | (126.60%) | |
| LFWD Lifeward Ltd. | $16.3M | — (loss-making) | — (loss-making) | +15.71% (above 0%: growing) | n/m | −52.77% (below 0%: shrinking) | 40.90% | (62.69%) | Compare |
| ARAY Accuray Incorporated | $14.8M | — (loss-making) | — (loss-making) | −7.90% (below 0%: shrinking) | n/m | −138.30% (below 0%: shrinking) | 0.00% | (42.19%) | Compare |
| CTSO Cytosorbents Corporation | $14.5M | — (loss-making) | — (loss-making) | +0.17% (above 0%: growing) | n/m | +64.90% (above 0%: growing) | 73.18% | (27.39%) | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | — (loss-making) | — | — | n/m | +47.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HSCS HeartSciences Inc. | $13.3M | — (loss-making) | — (loss-making) | −46.15% (below 0%: shrinking) | n/m | +18.18% (above 0%: growing) | 61.90% | (139,957.14%) | Compare |
| Median of peers | $15.5M | — | — | +0.17% | — | +32.48% | 30.87% | (52.44%) |